NUTEX HEALTH REPORTS 2025 FINANCIAL RESULTS AND ANNOUNCES SECOND STOCK REPURCHASE PROGRAM

Core Insights - Nutex Health reported significant financial growth for the fiscal year 2025, with total revenue reaching $875.3 million, an increase of 82.4% compared to $479.9 million in 2024 [1][2] - The company achieved an adjusted EBITDA of $259.6 million, reflecting a 152.6% increase from $102.8 million in 2024 [1][2] - Net income attributable to Nutex Health rose to $70.8 million in 2025, up from $52.1 million in 2024, marking an increase of $18.7 million [1][2] Financial Performance - Total assets as of December 31, 2025, were $918.5 million, with cash and cash equivalents of $185.6 million and long-term debt net of $29.2 million [1][2] - Operating income for 2025 was $275.6 million, compared to $130.7 million in 2024, representing a year-over-year improvement of $144.9 million [1][2] - The hospital division generated $844.2 million in revenue, a substantial increase of 188.0% from $449.1 million in 2024 [1][2] Operational Highlights - Total visits at the Hospital Division increased to 188,279 in 2025, up 11.8% from 168,388 in 2024 [1][2] - The company opened three new micro-hospitals in 2025, expanding its national footprint [2] - The company remediated all previously disclosed material weaknesses in internal controls over financial reporting in 2025, enhancing transparency and investor confidence [2] Stock Repurchase Program - The Board of Directors authorized a second stock repurchase program of up to $25.0 million to increase shareholder value and offset dilution from future stock compensation obligations [2][3] - The repurchase program allows the company to buy back shares in open market transactions or through privately negotiated transactions [2][3] Future Outlook - The company is well-positioned for continued growth through a balanced strategy that includes both new hospital development and increased patient volumes across existing facilities [2]